Celcuity Inc. (CELC)
CELCNext catalyst
Gedatolisib
PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer after endocrine therapy
Get an email about CELC's next catalysts
Track Celcuity Inc. (CELC) (CELC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (NDA filing).See the timeline
2 upcoming, 1 past
NDA Filing - gedatolisib
For PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer after endocrine therapy. The FDA accepted the sNDA for gedatolisib in PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer after endocrine therapy and set a PDUFA date of June 25, 2027.
SourceFDA PDUFA Date gedatolisib
For PIK3CA-mutant, HR-positive, HER2-negative advanced breast cancer after endocrine therapy. sNDA filing. AI-extracted from news: <![CDATA[FDA Accepts sNDA for Gedatolisib in PIK3CA-Mutant HR+/HER2β Breast Cancer]]>
SourceUpcoming FDA decisions
How CELC's past catalysts played out
Market Overview
Stock performance and key metrics
Gedatolisib
mCRPC (Metastatic Castration-resistant Prostate Cancer)
Ribociclib + Fulvestrant
Breast Cancer
Gedatolisib + Palbociclib + Letrozole
Breast Cancer
Gedatolisib + Palbociclib + Fulvestrant
Breast Cancer
Talazoparib
TNBC - Triple-Negative Breast Cancer
LY3023414
Endometrial Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Gedatolisib | Phase 3 | mCRPC (Metastatic Castration-resistant Prostate Cancer) | - | - |
Ribociclib + Fulvestrant | Phase 3 | Breast Cancer | - | - |
Gedatolisib + Palbociclib + Letrozole | Phase 3 | Breast Cancer | - | - |
Gedatolisib + Palbociclib + Fulvestrant | Phase 3 | Breast Cancer | - | - |
Talazoparib | Phase 2 | TNBC - Triple-Negative Breast Cancer | - | - |
LY3023414 | Phase 2 | Endometrial Cancer | - | - |
cancer
1 drug in this indication
HR+/HER2- PIK3CA wild-type locally advanced or metastatic breast cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Celcuity Inc. (CELC)'s drug pipeline?β
CatalystAlert tracks 6 drug candidates in Celcuity Inc. (CELC)'s (CELC) pipeline across Phase 3, Phase 2. Its lead program is Gedatolisib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Celcuity Inc. (CELC)'s next FDA catalyst?β
Celcuity Inc. (CELC)'s (CELC) next tracked catalyst is a PDUFA date expected Jun 25, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CELC biotech catalysts?β
Add CELC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Celcuity Inc. (CELC)'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
